Showing 352 results

Filters Content type: News, Editors' picks, About HIV Topic: PrEP science

Research, news and information on the effectiveness of oral pre-exposure prophylaxis (PrEP) and its impact on HIV epidemics, as well as clinical issues for PrEP users.

Side effects

CD4 and white blood cell declines caused by islatravir are dose-related and reversible, but rule out using it for prevention

News
27 October 2022
PrEP science

For Patients Taking PrEP, Poor Adherence Drives HIV Seroconversions

Editor's pick
Physician's Weekly
5 October 2022
New & experimental HIV treatments

Merck restarts islatravir HIV treatment studies, but abandons monthly PrEP

News
23 September 2022
New & experimental HIV treatments

Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection

Editor's pick
Merck press release
20 September 2022
Bone & joint problems

Vitamin D and calcium supplements suggested to avert bone disease in people taking tenofovir-based ART and PrEP

News
24 August 2022
Transgender people

Injectable PrEP is just as effective for transgender women as it is for gay men, study analysis finds

News
11 August 2022
PrEP science

New data suggest PrEP in pregnancy is safe

News
3 August 2022
Injectable & long-acting PrEP

Injectable and long-acting PrEP A research briefing

About HIV
July 2022
Sexually transmitted infections epidemiology

Nationwide Australian data shows PrEP has largely neutral effect on STI incidence

News
15 July 2022
PrEP science

On-Demand PrEP Works as Well as Daily Pills

Editor's pick
POZ
13 July 2022
PrEP science

'Real-world' study finds PrEP may be stopping 60% of HIV infections in French men at high risk of HIV

News
29 June 2022
PrEP

Truvada or Descovy: which should I take for PrEP?

About HIV
May 2022
PrEP policies & guidelines

PrEP Can Be Cost-Effective in Sub-Saharan Africa

Editor's pick
Contagion Live
16 May 2022
PrEP science

PrEP failures (breakthrough infections)

About HIV
May 2022
PrEP programmes & uptake

Four in ten PrEP recipients stop taking it within six months, global meta-analysis reveals

News
20 April 2022
PrEP science

Pregnant and breastfeeding cis women are paying the price for exclusion from PrEP research

News
5 April 2022
Kidney problems

PrEP and kidney function: who really needs screening and can event-based dosing reduce side-effects?

News
1 April 2022
Injectable & long-acting PrEP

No breakthrough HIV infections seen in women using injectable PrEP

News
25 March 2022
Bone & joint problems

Better adherence to PrEP is associated with more bone loss

News
9 March 2022
Transmission & prevention

Top 5 stories on HIV prevention from CROI 2022

News
1 March 2022
PrEP science

Long-acting doravirine implants as PrEP to prevent vaginal HIV transmission in mouse study

Editor's pick
i-Base
24 February 2022
Drug interactions & pharmacokinetics

No Interactions Between Hormone Therapy and PrEP in Transgender Women or Men

Editor's pick
NATAP
24 February 2022
Injectable & long-acting PrEP

Injected PrEP: breakthrough cases could have been detected sooner

News
22 February 2022
Injectable & long-acting PrEP

Injected PrEP: cabotegravir maintains its advantage over four years

News
17 February 2022